Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by HighVista Strategies LLC

HighVista Strategies LLC lifted its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 98.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,820 shares of the company's stock after buying an additional 257,496 shares during the period. HighVista Strategies LLC owned approximately 0.20% of Autolus Therapeutics worth $1,805,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. ProShare Advisors LLC purchased a new position in shares of Autolus Therapeutics during the second quarter worth about $43,000. Daiwa Securities Group Inc. boosted its position in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after purchasing an additional 15,293 shares during the period. Bayesian Capital Management LP purchased a new position in Autolus Therapeutics during the 1st quarter worth approximately $100,000. B. Riley Wealth Advisors Inc. purchased a new position in Autolus Therapeutics during the 1st quarter worth approximately $108,000. Finally, SG Americas Securities LLC acquired a new position in Autolus Therapeutics during the first quarter worth approximately $127,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AUTL has been the topic of a number of research reports. William Blair restated an "outperform" rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. Needham & Company LLC reissued a "buy" rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, June 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Autolus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.70.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock traded down $0.23 during mid-day trading on Monday, reaching $3.50. 986,529 shares of the company were exchanged, compared to its average volume of 1,404,654. The firm has a market cap of $931.13 million, a PE ratio of -2.94 and a beta of 2.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The firm's 50-day simple moving average is $4.09 and its two-hundred day simple moving average is $4.39. Autolus Therapeutics plc has a twelve month low of $2.01 and a twelve month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Equities analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.